Canadian Court Upholds Pfizer's Norvasc Patent

Law360, New York (April 17, 2008, 12:00 AM EDT) -- A Canadian federal court has upheld the validity of a Pfizer Inc. patent covering the active ingredient in blood pressure treatment Norvasc.

In a ruling Thursday, Judge Roger T. Hughes of the Canadian Federal Court prohibited Canada’s Minister of Health from approving Pharmascience Inc.'s generic version of Norvasc until Pfizer’s patent expires.

The patent-in-suit, Canadian Patent Number 1,321,393, covers amlodipine besylate, the active ingredient in Norvasc, and expires in August 2010, Pfizer said.

Judge Hughes said Montreal-based Pharmscience’s generic tablets could not be approved by the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.